Evaluating the risks and benefits of continuing versus withholding renin–angiotensin system inhibitors: a systematic review and meta-analysis with trial sequential analysis
Laila Shalabi , Ahmed Ibrahim , Sofian Zreigh , Mohamed Rifai , Shrouk Ramadan , Mohamed A. Arafa , Osama M. Mustafa , Muhammad Ansab , Mohamed F. Krayem , Ibrahim Elsabbagh , Nour H. Mash’al , Salem Waleed , Matthieu Legrand
{"title":"Evaluating the risks and benefits of continuing versus withholding renin–angiotensin system inhibitors: a systematic review and meta-analysis with trial sequential analysis","authors":"Laila Shalabi , Ahmed Ibrahim , Sofian Zreigh , Mohamed Rifai , Shrouk Ramadan , Mohamed A. Arafa , Osama M. Mustafa , Muhammad Ansab , Mohamed F. Krayem , Ibrahim Elsabbagh , Nour H. Mash’al , Salem Waleed , Matthieu Legrand","doi":"10.1016/j.bjao.2025.100405","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The best perioperative management of renin–angiotensin system inhibitors (RASi) in patients undergoing noncardiac surgery has been an ongoing debate as a result of inconclusive previous studies and insufficient data for robust guidelines. Although continuation of RASi may lead to intraoperative hypotension, withholding might also cause postoperative complications. Our meta-analysis aims to explore the postoperative outcomes of strategies of RASi management before surgery by evaluating randomised clinical trials, to provide more definitive conclusions for clinical practice.</div></div><div><h3>Methods</h3><div>We systematically searched PubMed, Scopus, Cochrane, and Web of Science until September 2024. Inclusion criteria included patients (≥18 yr) who underwent noncardiac surgery and received long-term RASi, which were either withheld or continued before surgery. Statistical analysis was conducted using R Studio version 4.4.2.</div></div><div><h3>Results</h3><div>A total of seven RCTs with 8741 patients receiving long-term RASi before noncardiac surgery revealed no significant difference between continuation and withholding groups regarding cardiovascular complications (risk ratio [RR] 0.94, 95% confidence interval [CI] 0.80–1.09, <em>P</em>=0.41), mortality (RR 1.16, 95% CI 0.55–2.43, <em>P</em>=0.71), and acute kidney injury (RR 0.95, 95% CI 0.84–1.06, <em>P</em>=0.33). However, continuation of RASi was associated with a higher incidence of intraoperative hypotension (RR 1.33, 95% CI 1.23–1.44, <em>P</em><0.001). Additionally, the incidence of postoperative severe hypertension (systolic BP >180 mm Hg) was significantly lower in the continuation group (RR 0.63, 95% CI 0.40–0.98, <em>P</em><0.002).</div></div><div><h3>Conclusions</h3><div>Continuing RASi before noncardiac surgery does not significantly impact mortality, cardiovascular complications or the risk of acute kidney injury. However, continuation is associated with an increased risk of intraoperative hypotension, and withholding with a higher risk of postoperative severe hypertension.</div></div><div><h3>Systematic review protocol</h3><div>CRD42024605208 (PROSPERO).</div></div>","PeriodicalId":72418,"journal":{"name":"BJA open","volume":"14 ","pages":"Article 100405"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BJA open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772609625000292","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background
The best perioperative management of renin–angiotensin system inhibitors (RASi) in patients undergoing noncardiac surgery has been an ongoing debate as a result of inconclusive previous studies and insufficient data for robust guidelines. Although continuation of RASi may lead to intraoperative hypotension, withholding might also cause postoperative complications. Our meta-analysis aims to explore the postoperative outcomes of strategies of RASi management before surgery by evaluating randomised clinical trials, to provide more definitive conclusions for clinical practice.
Methods
We systematically searched PubMed, Scopus, Cochrane, and Web of Science until September 2024. Inclusion criteria included patients (≥18 yr) who underwent noncardiac surgery and received long-term RASi, which were either withheld or continued before surgery. Statistical analysis was conducted using R Studio version 4.4.2.
Results
A total of seven RCTs with 8741 patients receiving long-term RASi before noncardiac surgery revealed no significant difference between continuation and withholding groups regarding cardiovascular complications (risk ratio [RR] 0.94, 95% confidence interval [CI] 0.80–1.09, P=0.41), mortality (RR 1.16, 95% CI 0.55–2.43, P=0.71), and acute kidney injury (RR 0.95, 95% CI 0.84–1.06, P=0.33). However, continuation of RASi was associated with a higher incidence of intraoperative hypotension (RR 1.33, 95% CI 1.23–1.44, P<0.001). Additionally, the incidence of postoperative severe hypertension (systolic BP >180 mm Hg) was significantly lower in the continuation group (RR 0.63, 95% CI 0.40–0.98, P<0.002).
Conclusions
Continuing RASi before noncardiac surgery does not significantly impact mortality, cardiovascular complications or the risk of acute kidney injury. However, continuation is associated with an increased risk of intraoperative hypotension, and withholding with a higher risk of postoperative severe hypertension.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
